Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Among patients with heart failure and a reduced ejection fraction, those who received the SGLT2 inhibitor empagliflozin had a significantly lower incidence of cardiovascular death or hospitalization for heart failure than those who received placebo.

Uloženo v:

Podrobná bibliografie
Vydáno v:	The New England journal of medicine Ročník 383; číslo 15; s. 1413 - 1424
Hlavní autoři:	Packer, Milton, Anker, Stefan D, Butler, Javed, Filippatos, Gerasimos, Pocock, Stuart J, Carson, Peter, Januzzi, James, Verma, Subodh, Tsutsui, Hiroyuki, Brueckmann, Martina, Jamal, Waheed, Kimura, Karen, Schnee, Janet, Zeller, Cordula, Cotton, Daniel, Bocchi, Edimar, Böhm, Michael, Choi, Dong-Ju, Chopra, Vijay, Chuquiure, Eduardo, Giannetti, Nadia, Janssens, Stefan, Zhang, Jian, Gonzalez Juanatey, Jose R, Kaul, Sanjay, Brunner-La Rocca, Hans-Peter, Merkely, Bela, Nicholls, Stephen J, Perrone, Sergio, Pina, Ileana, Ponikowski, Piotr, Sattar, Naveed, Senni, Michele, Seronde, Marie-France, Spinar, Jindrich, Squire, Iain, Taddei, Stefano, Wanner, Christoph, Zannad, Faiez
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Massachusetts Medical Society 08.10.2020
Témata:	Aged Antidiabetics Benzhydryl Compounds - adverse effects Benzhydryl Compounds - therapeutic use Cardiology and cardiovascular system Cardiovascular diseases Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control Congestive heart failure Death Diabetes Diabetes mellitus Diabetes Mellitus, Type 2 - complications Disease Progression Double-Blind Method Drug dosages Ejection fraction Female Genital tract Glomerular filtration rate Glomerular Filtration Rate - drug effects Glucosides - adverse effects Glucosides - therapeutic use Heart failure Heart Failure - complications Heart Failure - drug therapy Heart Failure - physiopathology Hospitalization Hospitalization - statistics & numerical data Human health and pathology Humans Kidney diseases Life Sciences Male Middle Aged Peptides Proportional Hazards Models Quality of life Renal Insufficiency, Chronic - complications Sodium-glucose cotransporter Sodium-Glucose Transporter 2 Inhibitors - adverse effects Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Statistical analysis Stroke Volume
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Among patients with heart failure and a reduced ejection fraction, those who received the SGLT2 inhibitor empagliflozin had a significantly lower incidence of cardiovascular death or hospitalization for heart failure than those who received placebo.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2022190